罗格列酮对腹膜透析患者微炎症反应状态的影响

探讨罗格列酮治疗对腹膜透析患者微炎症状态的影响。方法：收集我院持续性腹膜透析患者50例，随机分为两组，治疗组患者给予常规腹膜透析及罗格列酮4mg·d^-1，对照组常规腹膜透析治疗，两组均治疗12周。观察两组患者治疗前后空腹血糖（FBG）、糖化血红蛋白、血红蛋白、血清总胆固醇、高密度脂蛋白胆固醇（HDL—C）、低密度脂蛋白胆固醇、三酰甘油、高敏C反应蛋白（hs．CRP），肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、胰岛素抵抗指数（HOMA—JR）等指标变化。结果：治疗12周后，两组患者血FPG、HOMA—IR、hs．CRP、TNF-α、IL-6水平均有明显下降，HDL—C水平有明显升高，且与对照组比较差异具有统计学意义（P〈O．05）。结论：罗格列酮可改善腹膜透析患者微炎症反应状态及胰岛素抵抗，纠正脂代谢紊乱。

Effect of Rosiglitazone on Inflammation in Peritoneal Dialysis Patients

To assess the effect of rosiglitazone on inflammation in peritoneal dialysis patients. Methods： Fifty patients undergoing continuous ambulatory peritoneal dialysis were collected in our hospital. The treatment group was assigned to receive regular peritoneal dialysis and rosiglitazone 4mg once daily while the control group was received regular peritoneal dialysis for 12 weeks. Such serum examinations as fasting blood glucose （FBG） , glycosylated hemoglobin Alc, haemoglobin, serum total cholesterol, high density lipoprotein cholesterol（ HDL-C）, low density lipoprotein cholesterol, triglycerides and high sensitivity C reactive protein （hs-CRP） were measured, tumor necrnsis factoα（TNF-ct） and intedeukin-6 （IL-6） levels were measured by ELISA, and homeostasis model as- sessment of insulin resistance（HOMA-IR） was also evaluated before and after the treatment. Results： After the 12-week treatment by rosiglitazone, the levels of FPG, HOMA-IR, hs-CRP, TNF-α and IL-6 were declined significantly（ P 〈 0.05 ） , and the level of HDL- C was increased significantly（ P 〈 0.05 ）. Conclusion： Rosiglitazone shows significant anti-inflammatory, insulin resistance improve- ment and anti-lipidemic effects in peritoneal dialysis patients.